Opko Q2 FY26 net loss narrows to $8.4 million; revenue rises to $163.5 million

Reuters2026/07/27 20:16

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Opko Health Q2 2026 revenue rose 4.28% to $163.5 million; net loss narrowed to $8.4 million, or $0.01 per share.
Operating loss improved to $7 million from $60 million a year earlier.
Pharmaceuticals product revenue climbed to $42.9 million from $40.7 million, with Rayaldee revenue rising to $8.1 million from $7.2 million.
IP and other revenue more than doubled to $46.1 million, driven by $29.4 million recognized from shares received under a Nicoya agreement amendment.
Forecasts Q3 2026 total revenue of $131 million-$142 million; sees full-year total revenue of $560 million-$585 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607271605PRIMZONEFULLFEED9798760) on July 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Opko Q2 FY26 net loss narrows to $8.4 million; revenue rises to $163.5 million

You may also like

Crypto prices